MYOMO INC

Insider sales by Myomo’s CMO hint at cautious outlook—learn why recent Rule 144 moves could signal short‑term pressure on MYOMO’s price and investor sentiment.

Insider buying at MYOMO signals confidence and potential upside—investors see growth prospects, upcoming product launches, and strong shareholder value.

Insider sales at MYOMO show routine tax‑cover moves, not confidence loss—investors get a clearer view of stock value and future risk.

Insider sales at MYOMO INC show tax‑driven trades by its chief commercial officer, highlighting liquidity management amid a volatile stock and negative earnings multiple.

Investor insights: CFO Henry David A’s June 2026 sale is a routine tax‑cover move, not a distress signal, while heavy buying by Kirk Thomas shows board confidence.

Micah’s 90k‑share sale at Myomo signals a cautious rebalancing amid steep stock drops, yet senior holders still show confidence in long‑term recovery.

CEO Paul Gudonis buys 19,395 Myomo shares, boosting ownership to 48% and signaling confidence in the company’s robotic‑healthcare future.

CEO Paul Gudonis’s new RSU purchase fuels optimism for Myomo’s growth, showing insider confidence in exoskeleton innovation and potential upside for investors.

CEO Paul Gudonis’s 19,395‑RSU salary‑swap deal at Myomo signals insider confidence, aligns interests, and may calm volatility while boosting long‑term investor sentiment.

Insider buying surge at Myomo: Getz Heather C. adds 20k shares at $0.70, signaling confidence in medical robotics growth and a potential turnaround from its steep decline.